Targeting insulin-like growth factor - I receptor in breast cancer

TL;DRAbstract

Insulin-like growth factor-I receptor (IGF-IR) is integral to cancer cell proliferation, survival, migration, and invasion, and resistance to anti-cancer therapies in many human malignancies including breast cancer. Within the last few years several drugs targeting IGF-IR have entered clinical trials and are showing promising early results. One of the integral goals of my thesis is to identify patients who are most likely to benefit from therapy. The Lee Laboratory previously reported an IGF gene expression signature, based upon genes induced or repressed by IGF-I, which correlated with poor prognosis in breast cancer. Confirming that this signature can measure IGF activity, I report here that the signature is reversed in three different cancer models (cell lines or xenografts) treated with three different anti-IGF-IR therapies. The Lee laboratory originally reported that the IGF signature was present in triple-negative human breast cancers (TNBC), and I found here that the signature i

Chat with Paper

AI Agents for this Paper